Efficient GSH delivery using PAMAM-GSH into MPP-induced PC12 cellular model for Parkinson's disease

被引:19
作者
Sun, Hong-Ji
Wang, Yan
Hao, Tong
Wang, Chang-Yong
Wang, Qi-Yu
Jiang, Xiao-Xia [1 ,2 ]
机构
[1] Acad Mil Med Sci, Dept Adv Interdisciplinary Studies, Inst Basic Med Sci, 27 Taiping Rd, Beijing 100850, Peoples R China
[2] Acad Mil Med Sci, Tissue Engn Res Ctr, 27 Taiping Rd, Beijing 100850, Peoples R China
关键词
polyamidoamine; glutathione; MPP; PC12; cells; Parkinson's disease; ALPHA-SYNUCLEIN; GENE DELIVERY; GLUTATHIONE; DENDRIMERS; CELLS; APOPTOSIS; AGENTS; DIFFERENTIATION; NANOPARTICLES; DYSFUNCTION;
D O I
10.1093/rb/rbw032
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Glutathione (GSH) depletion has been an important contributor to the dysfunction of dopamine neurons. Polyamidoamine-GSH (PAMAM-GSH) was synthesized and the delivery effect of GSH into PC12 cells was tested. MTT assessment for cytotoxicity and reactive oxygen species (ROS) as well as nitrite oxide (NO) and intracelluar superoxide dismutase (SOD) detection for antioxidative ability were performed. Furthermore, the antiapoptotic ability was analysed by assessing caspase3, JNK1/2 and Erk1/2 expression. Our data indicated that PAMAM-GSH is an effective agent to replenish GSH into PC12 cells. PAMAM-GSH developed its antioxidative and protective ability for 1-methyl-4-phenylpyridinium (MPP)-induced PC12 cells by reducing the intracellular levels of ROS and SOD activity as well as decreasing the release of NO. Meanwhile, PAMAM-GSH could inhibit caspase-3 activation and might show its antiapoptotic ability to MPP-induced PC12 cells through JNK2/Erk1/2 pathway. In summary, these studies suggest that PAMAM-GSH conjugate has an intrinsic ability to penetrate PC12 cells and deliver GSH into these cells which may provide a new strategy for clinical applications in the treatment of Parkinson's disease.
引用
收藏
页码:299 / 307
页数:9
相关论文
共 56 条
  • [1] Dendrimer Internalization and Intracellular Trafficking in Living Cells
    Albertazzi, Lorenzo
    Serresi, Michela
    Albanese, Alberto
    Beltram, Fabio
    [J]. MOLECULAR PHARMACEUTICS, 2010, 7 (03) : 680 - 688
  • [2] Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25
  • [3] Nanoparticles of hydrophobically modified dextrans as potential drug carrier systems
    Aumelas, A.
    Serrero, A.
    Durand, A.
    Dellacherie, E.
    Leonard, M.
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 2007, 59 (01) : 74 - 80
  • [4] Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma
    Bai, Cheng Zhe
    Choi, Sunghyun
    Nam, Kihoon
    An, Songhie
    Park, Jong-Sang
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 445 (1-2) : 79 - 87
  • [5] Glutathione dysregulation and the etiology and progression of human diseases
    Ballatori, Nazzareno
    Krance, Suzanne M.
    Notenboom, Sylvia
    Shi, Shujie
    Tieu, Kim
    Hammond, Christine L.
    [J]. BIOLOGICAL CHEMISTRY, 2009, 390 (03) : 191 - 214
  • [6] Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial
    Bender, A.
    Koch, W.
    Elstner, M.
    Schombacher, Y.
    Bender, J.
    Moeschl, M.
    Gekeler, F.
    Mueller-Myhsok, B.
    Gasser, T.
    Tatsch, K.
    Klopstock, T.
    [J]. NEUROLOGY, 2006, 67 (07) : 1262 - 1264
  • [7] The cholinergic system and Parkinson disease
    Bohnen, Nicolaas I.
    Albin, Roger L.
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2011, 221 (02) : 564 - 573
  • [8] Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles
    Braun, CS
    Vetro, JA
    Tomalia, DA
    Koe, GS
    Koe, JG
    Middaugh, CR
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (02) : 423 - 436
  • [9] Motor Complications in Parkinson's Disease: Ten Year Follow-Up Study
    Cabo Lopez, Iria
    Garcia Ruiz, Pedro J.
    Vazquez Fernandez del Pozo, Silvia
    Sanchez Bernardos, Vicenta
    [J]. MOVEMENT DISORDERS, 2010, 25 (16) : 2735 - 2739
  • [10] Biochemical properties of new synthetic carnosine analogues containing the residue of 2,3-diaminopropionic acid: the effect of N-acetylation
    Cacciatore, I
    Cocco, A
    Costa, M
    Fontana, M
    Lucente, G
    Pecci, L
    Pinnen, F
    [J]. AMINO ACIDS, 2005, 28 (01) : 77 - 83